SCHEMBL26961919

SCHEMBL26961919

CC(C)(C)OC(=O)N[C@H]1CSc2ccc(C(=O)NNC(=O)C3CCN(C(=O)OCc4ccccc4)C3)cc2N(Cc2ccc(OC3CCCC3)cc2)C1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 3/20 0.43
▸ PDE4B Q07343 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.39
▸ HPGD P15428 2/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ MAPT P10636 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ KMT2A Q03164 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ PARP1 P09874 1/20 0.35
▸ PARP2 Q9UGN5 1/20 0.35
▸ NAAA Q02083 1/20 0.35
▸ PPARG P37231 1/20 0.35
▸ XIAP P98170 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ NPY1R P25929 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26961610 0.83 NPC1 (0.43) SRCALDH1A1NPSR1KMT2ANAAA
SCHEMBL26962000 0.82 PDE4B (0.40) SRCPDE4BSMN1; SMN2PPARGXIAP
SCHEMBL26961629 0.82 TP53 (0.39) SRCALDH1A1HPGDNPSR1MAPT
SCHEMBL29797033 0.80 SRC (0.42) SRCPDE4BALDH1A1HPGDNPSR1
SCHEMBL26962312 0.80 PDE4B (0.39) SRCPDE4BALDH1A1MAPTHTT
SCHEMBL26961694 0.80 MAPT (0.41) SRCALDH1A1HPGDNPSR1MAPT
SCHEMBL20264138 0.76 NPC1 (0.43) SRCALDH1A1NPSR1MAPTSMN1; SMN2
SCHEMBL26961658 0.76 XIAP (0.46) SRCALDH1A1MAPTXIAPTP53
SCHEMBL29796998 0.76 XIAP (0.46) SRCALDH1A1MAPTXIAPTP53
SCHEMBL29796993 0.75 NPC1 (0.43) SRCMAPTSMN1; SMN2XIAPTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368150-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2024-11-07 — — US disclosed
EP-4291558-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2023-12-20 — — EP disclosed
WO-2022171745-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2022-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368150-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER BICRA, BRD4, CNR1 SRC 2202/4885PDE4B 2683/4885ALDH1A1 1572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback